

Erratum to: Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial

Y. Miao · D. Dobre · H. J. Lambers Heerspink ·
B. M. Brenner · M. E. Cooper · H.-H. Parving ·
S. Shahinfar · D. Grobbee · D. de Zeeuw

Published online: 7 June 2011
© Springer-Verlag 2011

Erratum to: Diabetologia
DOI 10.1007/s00125-010-1922-6

Unfortunately, the values for urinary ACR in the ‘Month 6 characteristics’ section of Table 1 were incorrect. They should have read 124 (46–249) for those in the group with serum potassium <5.0 mmol/l and 139 (51–291) for those in the group with serum potassium \geq 5.0 mmol/l.

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00125-010-1922-6>.

Y. Miao · D. Dobre · H. J. Lambers Heerspink (✉) · D. de Zeeuw
Department of Clinical Pharmacology,
University Medical Centre Groningen,
Antonius Deusinglaan 1,
9713 AV Groningen, the Netherlands
e-mail: h.j.lambers.heerspink@med.umcg.nl

B. M. Brenner
Brigham and Women’s Hospital and Harvard School of Medicine,
Boston, MA, USA

M. E. Cooper
Baker IDI Heart and Diabetes Research Institute,
Melbourne, VIC, Australia

H.-H. Parving
Department of Medical Endocrinology,
University Hospital of Copenhagen,
Copenhagen, Denmark

H.-H. Parving
The Faculty of Health Science, Aarhus University,
Aarhus, Denmark

S. Shahinfar
Shahinfar Consulting, The Children’s Hospital of Philadelphia,
Philadelphia, PA, USA

D. Grobbee
Julius Center for Health Science and Primary Care,
University Medical Center Utrecht,
Utrecht, the Netherlands